^
Association details:
| Biomarker: | CDKN2A Negative + NRAS Mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.
Excerpt:
One pt with CDKN2A-/- NRAS mutant melanoma had a confirmed partial response….
DOI:
10.1200/jco.2013.31.15_suppl.2500
